Skip to main content
Premium Trial:

Request an Annual Quote

Rohan Hastie, John Ryals,

Rohan Hastie was named president and CEO of Metabolon. He replaces John Ryals, who retired from those posts, but will remain on the company's board. Ryals has been president, CEO, and a board member of Metabolon since April 2002, when he cofounded the firm. 

Hastie joined Metabolon in September 2017 as chief business officer. Before that, he was president of consulting firm Arrow Life Sciences & Healthcare. He also has held leadership positions in diagnostics and corporate development at Hologic, where he was most recently president of Hologic Diagnostic Solutions.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.